Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Key Takeaways Hims & Hers is now offering Zepbound and generic liraglutide for weight lossZepbound is priced at ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed ...

Joelle Pineau said she would step down effective May 30, creating an executive vacancy as the company aggressively invests and competes in the booming sector. Visa, Amex and Mastercard are all ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to ...

This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn't look like much ...